Multiple myeloma (MM) is a type of cancer that affects plasma cells in the bone marrow. BCMA is a protein found on these cancerous plasma cells, making it a great target for CAR-T therapy. IL15 BCMA CAR-T is a new and improved therapy where the CAR-T cells are designed to have IL15, a natural protein that helps T cells grow and stay active, attached to their surface.
This special design allows the CAR-T cells to kill multiple myeloma cells more effectively and to stay alive in the body longer. This helps patients stay in remission (cancer under control) for a longer period.